A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2001
11/01/2001	WO2001042306A3 Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
11/01/2001	WO2001036641A3 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
11/01/2001	WO2001036604A3 Nucleic acids encoding endotheliases, endotheliases and uses thereof
11/01/2001	WO2001034640A3 Peptide (virip) which inhibits a circulating virus in humans and the use thereof
11/01/2001	WO2000075338A3 CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF
11/01/2001	WO2000052147A9 Bacterial prolyl peptidases and methods of use
11/01/2001	WO2000040607A3 Tiam2 (t-cell lymphoma invasion and metastasis 2) nucleotide exchange factor
11/01/2001	WO2000034483A3 Compounds and methods for treatment and diagnosis of chlamydial infection
11/01/2001	WO2000032632A9 Allo- and auto-reactive t-cell epitopes from rhesus protein and their use
11/01/2001	US20010036928 Heterologous boosting immunizations
11/01/2001	US20010036919 Preventing airway mucus production by administration of EGF-R antagonists
11/01/2001	US20010036917 Therapeutic agents
11/01/2001	US20010036657 Aqueous solution; ion exchanging
11/01/2001	US20010036655 Vaccine
11/01/2001	US20010036635 Cancer screening
11/01/2001	US20010036463 Transcutaneous immunization for large particulate antigens
11/01/2001	US20010036462 Enhancing immunology response
11/01/2001	US20010036461 Human immunodeficiency virus vaccine
11/01/2001	US20010036460 Therapy for prostate cancer
11/01/2001	US20010036459 Cytotoxicity; therapeutic antibody
11/01/2001	US20010036458 Administering mixture of antigen and genetic engineered allogenic cell
11/01/2001	US20010036457 Anticancer agents
11/01/2001	US20010036452 Interleukin-1 muteins useful as vaccine adjuvants
11/01/2001	EP1144642A3 Compounds and methods for treatment and diagnosis of chlamydial infection
11/01/2001	CA2407523A1 Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
11/01/2001	CA2407517A1 Equine protozoal myeloencephalitis vaccine
11/01/2001	CA2407493A1 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
11/01/2001	CA2407455A1 Immunogenic pneumococcal protein and vaccine compositions thereof
11/01/2001	CA2407352A1 Compositions and methods for the therapy and diagnosis of acne vulgaris
11/01/2001	CA2407336A1 Method for treatment of tumors using photodynamic therapy
11/01/2001	CA2407167A1 Thrombopoietin receptor modulating peptide
11/01/2001	CA2407114A1 Compounds and methods for treatment and diagnosis of chlamydial infection
11/01/2001	CA2407074A1 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
11/01/2001	CA2407053A1 Pneumovirus ns proteins antagonize the interferon (ifn) response
11/01/2001	CA2406949A1 Use of particulate vectors in immunomodulation
11/01/2001	CA2406855A1 Novel insulin/igf/relaxin family polypeptides and dnas thereof
11/01/2001	CA2406639A1 A thymus expressed human cytochrome p450 (p450tec)
11/01/2001	CA2406004A1 Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
11/01/2001	CA2405961A1 Bispecific molecules and uses thereof
11/01/2001	CA2405632A1 Intrathecal administration of rituximab for treatment of central nervous system lymphomas
11/01/2001	CA2403916A1 Viral vectors for use in monitoring hiv drug resistance
10/2001
10/31/2001	EP1149913A1 Cytokine immunoconjugates
10/31/2001	EP1149910A1 Pharmaceutical composition for treating papillomavirus tumours and infection
10/31/2001	EP1149908A1 TGF-beta type receptor cDNAs and uses thereof
10/31/2001	EP1149906A1 Thrombopoietin receptor modulating peptide
10/31/2001	EP1149903A1 ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
10/31/2001	EP1149901A1 Pestivirus mutants and vaccines containing the same
10/31/2001	EP1149590A1 Use of gut peptide antibodies to improve feed efficiency
10/31/2001	EP1149589A1 Proteinaceous adjuvants
10/31/2001	EP1149588A1 Proteinaceous adjuvants
10/31/2001	EP1149587A2 Construction of Pasteurella heamolytica vaccines
10/31/2001	EP1149586A1 Bidirectional modulation of immunity
10/31/2001	EP1149167A2 Viral vaccine
10/31/2001	EP1149165A1 Basb055 polynucleotide and polypeptide from neisseria meningitidis. uses thereof
10/31/2001	EP1149164A2 Neisseria meningitidis polypeptides
10/31/2001	EP1149162A2 Medicament
10/31/2001	EP1149159A1 Human t cell effectors expressing cd86 molecule and therapeutic use thereof
10/31/2001	EP1149115A1 METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
10/31/2001	EP1149114A2 Polypeptides involved in immune response
10/31/2001	EP1149113A1 Use of agonists or antagonists of mip-3a in therapy
10/31/2001	EP1149111A1 Method and composition for angiogenesis inhibition
10/31/2001	EP1148902A1 Method of enhancing needleless transdermal powdered drug delivery
10/31/2001	EP1148885A1 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
10/31/2001	EP1148779A2 Expression of secreted human alpha-fetoprotein in transgenic animals
10/31/2001	EP0815141B1 Antibodies active against a fusion polypeptide comprising a histidine portion
10/31/2001	EP0699077B1 Hiv immunogenic complexes
10/31/2001	EP0519001B1 PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
10/31/2001	EP0444181B1 C-erbb-2 external domain: gp75
10/31/2001	EP0201540B2 Envelope antigens of lymphadenopathy associated virus and their applications
10/31/2001	DE10020505A1 RSV NS Proteine antagonisieren die Interferon (IFN) Antwort RSV NS proteins antagonize the interferon (IFN) response
10/31/2001	DE10018403A1 Preparing vaccine against cancer, useful for treatment or prevention, comprises coupling antibody mimetopes,selected from a phage-display library, to macromolecular carrier
10/31/2001	CN1320165A Antithrombin nucleotides and proteins from horn fly
10/31/2001	CN1320045A Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
10/31/2001	CN1320044A Combination therapies for B-cell lymphomas comprising administration of anti-CD 20 antibody
10/31/2001	CN1320043A Mutant cholera holotoxin as an adjuvant
10/31/2001	CN1320032A Alginate capsules for use in the treatment of brain tumor
10/31/2001	CN1319670A Foot-and-mouth disease virus gene engineered vaccine of domestic animal and preparation process thereof
10/31/2001	CN1319432A Broad-spectrum gene engineering nanometer vaccine for treating malignant tumour
10/31/2001	CN1073858C Stabilizer-containing live attenuated hepatitis A vaccine and its preparation
10/31/2001	CN1073857C Freeze-dried live attenuated hepatitis A vaccine and its preparation
10/30/2001	US6310193 Nucleotide sequences for use in the detection of microorganism; for use in screening bactericides
10/30/2001	US6310192 SigB
10/30/2001	US6310190 USPA1 and USPA2 antigens of Moraxella catarrhalis
10/30/2001	US6310184 Immunoglobulin for the treatment and prevention of mammary and prostate gland cancers
10/30/2001	US6310177 Compounds and methods for modulating tissue permeability
10/30/2001	US6310045 Compositions and methods for cancer immunotherapy
10/30/2001	US6310039 Tumor-inhibiting conjugates of proteins and polymers consisting of a suitable carrier system and cytostatic compounds
10/30/2001	US6309880 Antibodies specific for CD4-binding domain of HIV-1
10/30/2001	US6309873 Streptokinase mutants
10/30/2001	US6309867 Polypeptide; for use in controlling aging and cancer
10/30/2001	US6309854 Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
10/30/2001	US6309826 Diagnosing tumors; monitor tumorous tissue for nucleotide sequences coding tumor glycoprotein, compare to amount of nucleotide sequences coding tumor glycoprotein in healthy sample, classify cells
10/30/2001	US6309825 Analytical and therapeutic agents
10/30/2001	US6309819 Diagnostic and therapeutic system for Crohn's disease and Colitia ulcerosa
10/30/2001	US6309674 Administering smilax china, or similiar plant extract
10/30/2001	US6309671 Stable glassy state powder formulations
10/30/2001	US6309669 Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
10/30/2001	US6309651 A method of inhibiting, moderating or diagnosing pseudomonas aeruginosa infection is disclosed.
10/30/2001	US6309650 Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
10/30/2001	US6309649 The fusion (f) protein, attachment (g) protein and matrix (m) protein of respiratory syncytial virus (rsv) are isolated and purified.

1 ... 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 ... 1823